Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Getting Through To Autism: Seaside Pioneers New Drugs

This article was originally published in Start Up

Executive Summary

Tiny Seaside Therapeutics is doing pioneering work to develop disease-modifying drugs for Autism Spectrum Disorders, a group of syndromes that not long ago was thought immutable and even blamed on bad parenting. By targeting molecular pathways associated with the single gene disorder fragile X syndrome, Seaside hopes to extrapolate its work to other “autisms” and help people most affected by those disorders learn to walk, talk, or even live independent lives.

You may also be interested in...



Pfizer Revamps Neuroscience R&D – New Site, New Mandate, New Leadership

Pfizer has thoroughly revamped its approach to neuroscience R&D, emphasizing disease biology and neural circuitry, moving its research team from Groton, Conn. to Cambridge, Mass., and hiring an eminent neuroscientist to lead the group.

NIH Pilots Virtual Pharma Portfolio In Neurology

With a last round of applications due Oct. 8, the Neurotherapeutics Network is hoping for increased industry participation in a portfolio of 20 projects in the hit-to-lead-optimization stage that will have access to CROs under contract to NIH. Projects that continue to meet milestones will be supported through proof-of-concept in humans.

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC092367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel